Preclinical Radiotracers Used in Direct Targeting and Pretargeting Approaches
| Tumor or disease | Radiolabeled agent | bsAb | Molecular target | Reference |
|---|---|---|---|---|
| Direct targeting | ||||
| Melanoma | [131I]I-KN046 | KN046 | PDL1, CTLA4 | (28) |
| Breast cancer brain metastasis | [89Zr]Zr-DFO-HER3-HBP-DOX | Nanoparticle (HBP) biodistribution | HER3/PEG | (29) |
| [89Zr]Zr-mesothelin HLE BiTE | BiTE | CD3, mesothelin | (30) | |
| [89Zr]Zr-DFO-bintrafusp | Bintrafusp | PDL1, TGF-betaRII | (31) | |
| [89Zr]Zr-DFO-amivantamab | Amivantamab | CMET, EGFR | (32) | |
| [89Zr]Zr-DFO-muS110 | muS110 | CD3, EpCAM | (33) | |
| Breast cancer | [89Zr]Zr-Df-ATG-101 | AT-101 | PD-L1, 4-1BB | (34) |
| Liver cancer | [89Zr]Zr-DFO-ERY974 | ERY974 | CD3, GPC3 | (35) |
| Prostate cancer | [64Cu]Cu-NODAGA-bsAb | bsAb | PSMA, CD3 | (36) |
| [89Zr]Zr-DFO-PSMAxCD3 | PSMAxCD3 | PSMA, CD3 | (37) | |
| [89Zr]Zr-DFO-DLL3-scFv | DLL3-scFv | CD3, DLL3 | (38) | |
| Pancreatic ductal adenocarcinoma | [111In]In-CD3xTRP1 | CD3xTRP1 | CD3, TRP1 | (39) |
| Ovarian cancer | [89Zr]Zr-DFO-REGN4018 | REGN4018 | CD3, MUC16 | (2) |
| Colon carcinoma | [64Cu]Cu-DOTA-dbBITE | dbBITE | CEA, CD3 | (40) |
| [89Zr]Zr-DFO-IBI322 | IBI322 | PDL1, CD47 | (41) | |
| Colorectal cancer | [89Zr]Zr-FAP-4–1BBL | FAP-4-1BBL | 4-1BB, FAP | (42) |
| [89Zr]Zr-DFO-10G1 | 10G1 | CD3, RON | (43) | |
| [124I]I-AK104 | AK104 (cadonilimab) | hPD1, CTLA4 | (44) | |
| Pretargeting | ||||
| Colorectal cancer | [111In]In-RDC018 | TF2 | CEA, HSG | (8) |
| [86Y]Y-DOTA-Bn | Anti-GPA33/anti-DOTA | GPA33, DOTA | (4) | |
| [111In]In-Pr | DOTA-PRIT | GPA33, DOTA | (9) | |
| Neuroblastoma | [86Y]Y-DOTA | P53-SADA-bsAb | Antiganglioside GD2, DOTA | (10) |
| Breast cancer | [64Cu]Cu-MeCOSar-NHS-PEG | anti-PEG/anti-EGFR | PEG, epidermal growth factor receptor | (45) |